SCHEMBL25588122

SCHEMBL25588122

CCN(C[C@H]1CCc2cc(-c3nnn(C)n3)c(C)nc2N1)C(=O)[C@@H](C)c1ccc(OC(F)F)nc1

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 10/20 0.47
▸ HCRTR1 O43613 1/20 0.31
▸ ITGAV P06756 1/20 0.31
▸ ITGB6 P18564 1/20 0.31
▸ ITGB8 P26012 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588109 0.94 MC4R (0.46) MC4RITGAVITGB6ITGB8
SCHEMBL25587769 0.77 MC4R (0.49) MC4R
SCHEMBL25587380 0.77 MC4R (0.58) MC4R
SCHEMBL25588374 0.76 MC4R (0.47) MC4R
SCHEMBL25588494 0.76 MC4R (0.41) MC4R
SCHEMBL25587072 0.76 MC4R (0.43) MC4R
SCHEMBL24940698 0.74 MC4R (0.83) MC4R
SCHEMBL31139120 0.74 MC4R (0.83) MC4R
SCHEMBL24940017 0.74 MC4R (0.83) MC4R
SCHEMBL25587615 0.74 PTGDR2 (0.36) MC4RHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR PFIZER INC. (US) 2023-06-08 — — US disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR MC4R, MC2R, NPY4R MC4R 1/4885HCRTR1 30/4885ITGAV 3405/4885
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof MC4R, MC3R, MC5R MC4R 1/4885HCRTR1 51/4885ITGAV 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback